1 |
GROOTAERT M O J, BENNETT M R. Vascular smooth muscle cells in atherosclerosis: time for a reassessment[J]. Cardiovasc Res, 2021, 117(11): 2326-2339.
|
2 |
GUIJARRO C, COSÍN-SALES J. LDL cholesterol and atherosclerosis: the evidence[J]. Clin Investig Arterioscler, 2021, 33(): 25-32.
|
3 |
KATTOOR A J, POTHINENI N V K, PALAGIRI D, et al. Oxidative stress in atherosclerosis[J]. Curr Atheroscler Rep, 2017, 19(11): 42.
|
4 |
DEROISSART J, PORSCH F, KOLLER T, et al. Anti-inflammatory and immunomodulatory therapies in atherosclerosis[J]. Handb Exp Pharmacol, 2022, 270: 359-404.
|
5 |
庞树朝, 张军平, 陈美玲, 等. 中医药治疗动脉粥样硬化新进展[J]. 中华中医药杂志, 2017, 32(1): 214-217.
|
6 |
中国医师协会中西医结合分会心血管专业委员会, 中中医药学会心血管病分会. 动脉粥样硬化中西医防治专家共识(2021年)[J]. 中国中西医结合杂志, 2022, 42(3): 287-293.
|
7 |
张艺嘉, 樊 珂, 崔小数, 等. 中医药治疗动脉粥样硬化临床研究进展[J]. 中医学报, 2020, 35(9): 1908-1912.
|
8 |
吴晶魁, 杨 乔, 李洋洋, 等. 水蛭通过p38MAPK信号通路对早期动脉粥样硬化大鼠VSMCs的影响[J]. 中国中药杂志, 2017, 42(16): 3191-3197.
|
9 |
王 群, 杨关林, 贾连群, 等. 基于网络药理学探讨何首乌治疗动脉粥样硬化作用机制[J]. 辽宁中医药大学学报, 2019, 21(9): 136-139.
|
10 |
郑云霞, 孟 萌. 中药丹参治疗冠心病的药理成分及作用分析[J]. 双足与保健, 2018, 27(17): 190-191.
|
11 |
任超,王萍,闫东明,等.三七总皂苷对AS小鼠的治疗作用[J].中国药理学通报,2018,34(9):1289-1295.
|
12 |
甄庆强, 张 洁, 雷 震, 等. 瓜蒌皮提取物对同型半胱氨酸诱导动脉粥样硬化的保护作用[J]. 东南大学学报(医学版), 2018, 37(2): 239-243.
|
13 |
于进.天麻酚性成分抗AS的实验研究[D].昆明:云南中医药大学,2019.
|
14 |
荆文光, 符 江, 刘玉梅, 等. 水蛭的化学成分[J]. 中国实验方剂学杂志, 2014, 20(19): 120-123.
|
15 |
李国强, 李韵仪, 李 桃, 等. 水蛭的化学成分研究[J]. 天津中医药, 2018, 35(9): 703-705.
|
16 |
许石钟. 水蛭经炮制后的化学成分变化研究[J]. 陕西中医, 2018, 39(7): 980-982.
|
17 |
朱 迪, 曹烨民. 动脉粥样硬化抗炎治疗的研究进展[J]. 中国现代医学杂志, 2023, 33(5): 50-55.
|
18 |
WOLF D, LEY K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019, 124(2): 315-327.
|
19 |
BÄCK M, YURDAGUL A Jr, TABAS I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities[J]. Nat Rev Cardiol, 2019, 16(7): 389-406.
|
20 |
李思瑞, 冯泽清, 吴玉章. C1632通过MAPK和NF-κB抑制巨噬细胞M1型极化[J]. 免疫学杂志, 2022, 38(3): 185-192.
|
21 |
ZHOU X, XU S N, YUAN S T, et al. Multiple functions of autophagy in vascular calcification[J]. Cell Biosci, 2021, 11(1): 159.
|
22 |
BENNETT M R, SINHA S, OWENS G K. Vascular smooth muscle cells in atherosclerosis[J]. Circ Res, 2016, 118(4): 692-702.
|
23 |
MARCOVECCHIO P M, THOMAS G D, MIKULSKI Z, et al. Scavenger receptor CD36 directs nonclassical monocyte patrolling along the endothelium during early atherogenesis[J]. Arterioscler Thromb Vasc Biol, 2017, 37(11): 2043-2052.
|
24 |
DONG X Z, HU H J, FANG Z D, et al. CTRP6 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration[J]. Biomedecine Pharmacother, 2018, 103: 844-850.
|
25 |
NEWBY A C, GEORGE S J. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies[J]. Cardiovasc Res, 1993, 27(7): 1173-1183.
|
26 |
ZHANG S G, ZHANG S H, LIANG X, et al. Guanxinping ameliorates atherosclerosis via MAPK/NF-κB signaling pathway in ApoE-/- mice[J]. Perfusion, 2023, 38(3): 557-566.
|
27 |
ZEBOUDJ L, GIRAUD A, GUYONNET L, et al. Selective EGFR (epidermal growth factor receptor) deletion in myeloid cells limits atherosclerosis-brief report[J]. Arterioscler Thromb Vasc Biol, 2018, 38(1): 114-119.
|
28 |
VLACIL A K, SCHUETT J, RUPPERT V, et al. Deficiency of Nucleotide-binding oligomerization domain-containing proteins (NOD) 1 and 2 reduces atherosclerosis[J]. Basic Res Cardiol, 2020, 115(4): 47.
|
29 |
HANG M, LI F, WANG X, et al. MiR-145 alleviates Hcy-induced VSMCs proliferation, migration, and phenotypic switch through repression of the PI3K/Akt/mTOR pathway[J]. Histochem Cell Biol,2020,153:357-366.
|
30 |
李文倩. 齐墩果酸经FGF2/JNK/PON2通路抑制ox-LDL诱导的大鼠血管平滑肌细胞增殖[D]. 青岛: 青岛大学, 2018.
|
31 |
梁文静. 糖尿病及血管新生因子对动脉粥样硬化斑块不稳定性的影响及作用机制[D]. 济南: 山东大学, 2018.
|
32 |
LEE J G, KAY E P. NF-κB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in cornea[J]. Invest Ophthalmol Vis Sci, 2012, 53(3): 1530-1538.
|
33 |
朱 莹. FGF/FGFR3与非经典NF-κB信号通路的交互作用及其在多发性骨髓瘤细胞增殖中的意义[D]. 重庆: 第三军医大学, 2013.
|